Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level

Rohit Aggarwal,Siamak Moghadam-Kia,David Lacomis,A Malik,Zengbiao Qi,Diane Koontz,Rw Burlingame,Chester V. Oddis

Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level

2019

Rohit Aggarwal
Siamak Moghadam-Kia
David Lacomis
A Malik
Zengbiao Qi
Diane Koontz
Rw Burlingame
Chester V. Oddis

Objective: To evaluate clinical associations of anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody (Ab) and statin exposure in necrotizing myopathy (NM) patients.Methods: NM w...

Keywords:

Physical therapy
Reductase
Antibody
Necrotizing myopathy
Medicine
Cancer
Coenzyme A
Diabetes mellitus
Pharmacology
Statin
Autoantibody level
Internal medicine
cancer risk
Gastroenterology
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations